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Abstract Studies of the the three-dimensional quantitative
structure–activity relationships for ninety-five c-kit tyrosine
kinase inhibitors were performed. Based on a co-
crystallized compound (1 T46), known inhibitors were
aligned with c-kit by induced-fit docking, and multiple
training/test set splitting was performed to validate the
selected pharmacophore model. The best pharmacophore
model consisted of five features: one hydrogen-bond donor
and four aromatic rings. Reliable statistics were obtained
(R2=0.95, Rpred
2=0.75), and the model was validated by
using it to select c-kit inhibitors from a database; 82.1% of
the hits it retrieved were active. Accordingly, our model can
be reliably used to identify new c-kit inhibitors, and can
provide useful information when designing new inhibitors.
Keywords C-kit . 3D-QSAR . Kohonen maps . Induced-fit
docking
Introduction
The c-kit proto-oncogene encodes a transmembrane tyro-
sine kinase receptor that is activated by the stem cell factor
(SCF), its natural ligand. C-kit protein plays a critical role
in modulating histamine release from mast cells [1, 2]
following its binding with SCF, which leads to dimerization
and autophosphorylation at specific tyrosine residues. More-
over, signaling by c-kit plays an important role in cellular
transformation and differentiation, including proliferation,
survival, adhesion, and chemotaxis [3]. The overexpression
of the c-kit proto-oncogene has been reported in hematopoi-
etic cells, small cell lung cancer, and gastrointestinal stromal
tumors [4–6]. Furthermore, it has been demonstrated that
mutations of c-kit protect human colon adenocarcinoma cells
against apoptosis and enhance their invasive potential [7].
The clinical importance of c-kit expression in tumors has led
to research focused on finding inhibitors of this tyrosine
kinase. Imatinib (Gleevec®) was the first such compound to
be used in therapy, but mutations of c-kit led to reduced
efficacy or a complete lack of efficacy of this treatment.
Other compounds are likely to be effective against mutants,
such as sunitinib (Sutent®), but the need for new and more
effective inhibitors is still critical. In this paper, we report a
three-dimensional quantitative structure–activity relationship
(3D-QSAR) analysis of 95 known c-kit inhibitors that were
initially docked into the crystal structure of c-kit by means of
a mixed approach including molecular dynamics and
docking (induced fit). The model obtained revealed interest-
ing features that should be considered during the design and
development of new potentially active candidates targeting
this kinase, which could be useful as anticancer agents.
Materials and methods
Dataset for analysis
A dataset of 95 compounds (2-aminobenzoxazole deriva-
tives [8], 3-aminobenzoisoxa(thi)azole derivatives [9, 10],
thienopyrimidine derivatives [11], and anilinophthalazine
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derivatives [12]) was selected for the present study (Table
1). Their pIC50 values were used as a dependent variable in
the QSAR models. In order to validate each model, the
inhibitors were split into a training set and a test set. Two
different splitting methods were applied. The first method
involved automated random selection, while the second
involved a Kohonen map artificial neural network (ANN)
or self-organizing maps (SOM) [13, 14]. Due to their
clustering capabilities, Kohonen maps ensure that both sets
are homogeneously distributed within the entire area of
descriptor space. The test compounds were selected by
evaluating the minimum distance from the centroid of each
cell in the top map. Selection in this manner allows
predictions to be made by interpolation and not extrapola-
tion from the domain of the particular QSAR model [15].
Descriptor calculations were carried out using the
CODESSA software package [16], and descriptor space
was explored using Kohonen maps for autoscaled data.
This structural information was used to build a Kohonen
map (five per five neurons, 300 epochs) [17]. After 300
epochs of net training, similar compounds are clustered
together in the multi-dimensional descriptor space. In each
splitting method, 76 of the 95 inhibitors were chosen for a
training set and 19 were selected as a test set (Table 1).
Ligand preparation
The 95 ligands were processed with the LigPrep software
package in order to assign the appropriate protonation states
to them at physiological pH(7.2±0.2), employing the
Ionizer option. Conformers were generated through Macro-
Model torsional sampling using the OPLS_2005 force field
[18].
Induced-fit docking
Generated conformers were docked into the c-kit crystallo-
graphic structure (PDB: 1 T46), which was originally
complexed with imatinib, and the best score poses for each
ligand were used to generate pharmacophore hypotheses.
The mixed molecular docking/dynamics protocol called
induced-fit docking (IFD) [19] was used. In an interative
manner, this approach combines ligand-docking techniques
with those used to model receptor conformational changes.
The Glide docking software package [20] was used for
ligand flexibility, while the refinement module in the Prime
program [21] was used to account for receptor flexibility:
the degrees of freedom of side chains were mainly sampled,
while minor backbone movements were allowed through
minimization. The strategy used was to first dock ligands
into a rigid receptor using a softened energy function such
that steric clashes do not prevent at least one pose from
assuming a conformation close to the correct one (the
“ligand sampling step”). The degrees of freedom of the
receptor were then sampled, and global ligand/receptor
energy minimization was performed for many ligand poses;
this attempted to identify low free-energy conformations of
the whole complex (the “protein sampling step”). After
that, a second ligand docking step was performed on the
refined protein structures, using a hard potential function to
sample the ligand’s conformational space within the refined
protein environment (the “ligand resampling step”). Finally,
a composite score function was applied to rank the
complexes; this accounted for the receptor/ligand interac-
tion energy as well as strain and solvation energies (the
“scoring step”). The composite score, which was used to
perform the final ranking of the compounds, was derived as
follows:
IFScore ¼ GlideScoreþ 0:05PrimeEnergy: ð1Þ
3D-QSAR pharmacophore modeling
The 3D-QSAR study was performed using the Phase
software package [22]. Phase utilizes fine-grained confor-
mational sampling and a range of scoring techniques to
identify common pharmacophore hypotheses. These con-
vey characteristics of 3D chemical structures that are
reported to be critical for binding. The pharmacophore
model was developed by using a set of pharmacophore
features to generate sites for all of the compounds. Each
structure was represented by a set of points in 3D space that
coincided with various chemical features which facilitated
noncovalent binding between the ligand and its binding
pocket. Phase provides a standard set of six pharmacophore
features: hydrogen-bond acceptor (A), hydrogen-bond
donor (D), hydrophobic group (H), negatively ionizable
(N), positively ionizable (P), and aromatic ring (R).
Hypotheses were generated by systematically varying the
number of sites (nsites) and the number of matching active
compounds (nact). With nact=nact_tot initially (nact_tot is the
total number of active compounds in the training set), nsites
was decreased from its initial value of 7 until at least one
hypothesis was found and scored successfully. In this study,
with nsites=5 and nact=nact_tot=8, common pharmacophores
were examined using a scoring protocol to identify the
pharmacophore from each surviving n-dimensional box that
yielded the best alignment of the active-set ligands. The
scoring protocol allows the different hypotheses to be
ranked so that the most appropriate can be chosen for
further investigation. Inactive molecules were also scored,
in order to observe the alignment of these molecules with
the pharmacophore hypotheses and to select the best ones.
The larger the difference between the scores of the actives
and inactives, the better the hypothesis is at discriminating
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Table 1 Actual and predicted pIC50 values of compounds included in the study
Random selection Kohonen map Random Kohonen
Compound Actual pIC50 Pred. pIC50 Actual pIC50 Pred. pIC50 Pharm set QSAR set QSAR set
1 5.602 5.59 5.602 5.63 Inactive Test Training
2 6.000 5.83 6.000 5.76 Inactive Training Test
3 5.854 5.76 5.854 5.39 Inactive Training Training
4 5.523 5.58 5.523 5.70 Inactive Training Test
5 5.102 5.12 5.102 5.09 Inactive Training Training
6 6.155 5.79 6.155 5.90 Test Training
7 5.456 5.56 5.456 5.45 Inactive Training Training
8 5.699 5.83 5.699 5.86 Inactive Test Training
9 5.569 5.63 5.569 5.81 Inactive Training Training
10 7.495 7.65 7.495 7.20 Training Training
11 8.046 7.92 8.046 8.04 Active Training Training
12 7.553 7.58 7.553 7.47 Training Test
13 8.222 7.95 8.222 8.00 Active Training Training
14 7.167 7.32 7.167 7.10 Training Training
15 7.081 7.08 7.081 7.28 Training Test
16 7.301 7.17 7.301 7.54 Test Training
17 7.721 7.07 7.721 7.00 Test Test
18 7.824 7.73 7.824 7.54 Training Training
19 7.569 7.12 7.569 7.17 Test Test
20 7.481 7.64 7.481 7.62 Test Training
21 6.959 6.67 6.959 6.90 Training Training
22 7.658 6.80 7.658 7.72 Test Training
23 7.538 7.55 7.538 7.46 Training Training
24 7.301 7.51 7.301 7.91 Training Test
25 7.319 7.35 7.319 7.25 Training Training
26 6.854 6.88 6.854 7.16 Training Training
27 7.367 7.37 7.367 7.39 Training Training
28 7.721 7.80 7.721 7.24 Training Training
29 6.757 6.62 6.757 6.76 Training Training
30 6.740 6.71 6.740 6.86 Training Training
31 6.796 6.46 6.796 6.98 Test Training
32 6.398 6.36 6.398 6.53 Training Training
33 6.032 6.06 6.032 6.14 Training Training
34 6.237 6.28 6.237 6.14 Training Training
35 6.237 6.23 6.237 5.80 Training Training
36 6.097 6.22 6.097 6.12 Training Training
37 7.086 7.28 7.086 7.29 Training Training
38 6.102 6.06 6.102 5.97 Training Training
39 6.018 5.97 6.018 5.90 Training Training
40 7.432 7.38 7.432 7.24 Training Training
41 6.444 6.33 6.444 6.26 Training Training
42 7.585 7.67 7.585 7.33 Training Training
43 6.092 6.03 6.092 6.79 Training Test
44 7.569 7.58 7.569 7.78 Training Training
45 6.699 7.19 6.699 6.87 Test Training
46 6.745 6.92 6.745 7.04 Training Training
47 7.420 7.45 7.420 7.58 Training Training
48 7.268 7.25 7.268 7.51 Training Test
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Table 1 (continued)
Random selection Kohonen map Random Kohonen
Compound Actual pIC50 Pred. pIC50 Actual pIC50 Pred. pIC50 Pharm set QSAR set QSAR set
49 7.553 7.55 7.553 7.79 Training Training
50 7.167 7.22 7.167 6.98 Training Test
51 7.523 7.46 7.523 7.47 Training Training
52 7.523 7.47 7.523 6.76 Training Test
53 4.830 4.74 4.830 5.37 Inactive Training Test
54 5.352 5.98 5.352 5.32 Inactive Test Training
55 7.638 7.59 7.638 7.32 Training Test
56 6.943 7.02 6.943 7.07 Training Training
57 6.102 6.10 6.102 6.00 Training Training
58 5.580 5.28 5.580 5.55 Inactive Training Training
59 7.796 7.44 7.796 8.07 Training Test
60 7.796 7.33 7.796 8.04 Test Training
61 7.745 8.04 7.745 7.85 Training Test
62 7.678 7.86 7.678 7.65 Training Training
63 6.780 6.80 6.780 6.77 Training Training
64 4.630 4.98 4.630 5.43 Inactive Training Training
65 7.921 7.73 7.921 7.73 Training Training
66 8.398 8.45 8.398 8.08 Active Training Training
67 7.854 7.88 7.854 7.56 Training Training
68 7.959 7.75 7.959 7.96 Test Training
69 8.155 7.97 8.155 7.77 Active Training Training
70 8.000 7.84 8.000 7.75 Active Training Training
71 8.301 8.08 8.301 8.09 Active Training Training
72 7.569 7.75 7.569 7.76 Training Training
73 8.301 8.28 8.301 7.75 Active Training Test
74 8.155 7.90 8.155 7.96 Active Test Training
75 6.991 7.08 6.991 7.08 Training Training
76 7.432 6.85 7.432 7.09 Test Training
77 6.470 6.79 6.470 6.68 Test Training
78 7.921 7.80 7.921 7.70 Training Training
79 7.208 7.42 7.208 7.37 Training Training
80 7.444 7.57 7.444 7.59 Training Training
81 7.854 7.93 7.854 7.74 Training Test
82 7.620 7.63 7.620 7.64 Training Training
83 7.301 7.36 7.301 7.63 Training Training
84 7.367 7.22 7.367 7.32 Training Training
85 7.252 7.08 7.252 6.86 Test Training
86 7.143 7.28 7.143 7.33 Training Training
87 7.638 7.66 7.638 7.63 Training Test
88 7.194 7.10 7.194 7.35 Training Training
89 6.666 6.95 6.666 6.95 Training Training
90 6.532 6.49 6.532 7.27 Training Test
91 6.943 6.89 6.943 6.93 Training Training
92 6.943 6.91 6.943 7.00 Test Training
93 7.149 7.25 7.149 7.34 Training Training
94 7.149 6.70 7.149 7.32 Test Training
95 8.097 7.89 8.097 8.21 Active Training Training
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active from inactive molecules. For QSAR development,
models of the pharmacophore features of training-set
molecules were placed into a regular grid of cubes, with
each cube allotted zero or more “bits” to account for the
different types of pharmacophore features in the training-set
molecule that occupy the cube (1 Å). This representation
gave rise to binary-valued occupation patterns that could be
used as independent variables to create partial least-squares
(PLS) factor 3D-QSAR models. Statistics on the correlation
of the predicted with the actual activity data were collated
for the hypothesis. Phase QSAR models can be either atom-
based or pharmacophore-based, the difference being wheth-
er all atoms are taken into account, or whether only the
pharmacophore sites that can be matched to the hypothesis
are considered. The choice of model depends largely on
whether or not the training-set molecules are sufficiently
rigid and congeneric. If the structures contain a small
number of rotatable bonds and have some of their structural
framework in common, then an atom-based model may
work quite well [22]. The selected dataset did not have
many rotatable bonds, so the atom-based QSAR model was
used.
Results and discussion
We started our work by redocking imatinib into the protein
via the IFD approach in order to evaluate the reliability of
the computational algorithm before carrying out receptor-
guided alignment of the inhibitors. Training alignment of
imatinib gave good results in terms of both IF score
(crystallized score=−12.28; docked=−12.51), descriptor
contributions (crystallized: Hbond=−1.5, vdW=−66.1,
Coul=−9.1; docked: Hbond=−1.4, vdW=−66.8, Coul=−9.1),
and root mean square deviation (RMSD=0.43) (Fig. 1).
Thus, it was possible to align the selected inhibitors using
the same approach. The top-ranked binding poses,
selected by IFD score and by visual inspection, were used
to generate the pharmacophore hypotheses (Fig. 2). The
3D-QSAR studies were carried out using the Phase
package from Schrödinger LLC. To find the common
pharmacophore hypothesis, the dataset was split into an
active set and an inactive set (the “pharm” set) (Table 1).
Compounds with pIC50>8.00 were considered to be
active, those with pIC50<6.00 were considered to be
inactive, whereas those in-between were considered to be
moderately active. Three hundred sixty-one hypotheses
were identified (Table 2). Generated hypotheses were
submitted to a Phase scoring procedure consisting of three
scores: survival was calculated solely on the basis of the
active set; surv-inactive was calculated on the basis of the
active and inactive sets; post-hoc was calculated on the
Fig. 1 Superposition of co-crystallized imatinib (yellow) and IFD
(red)
Fig. 2 Docked structures of the most active compounds
Table 2 Identified pharmacophore hypotheses
Variant Max no. of hypotheses
ARRRR 5
ADHRR 7
ADDRR 97
DDRRR 45
AADRR 58
DRRRR 21
AADHR 4
AADDR 49
AARRR 5
ADRRR 70
361
A H-acceptor, D H-donor, H hydrophobic, R aromatic ring
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Table 3 Best pharmocophore hypotheses
Hypothesis Survival Surv-inact Post-hoc Site Vector Volume Selectivity
DDRRR.174 3.690 2.161 6.180 0.90 0.994 0.795 1.852
DDRRR.178 3.690 2.161 6.180 0.90 0.994 0.795 1.852
DRRRR.240 3.686 2.177 6.177 0.90 0.986 0.805 1.981
DRRRR.241 3.686 2.177 6.177 0.90 0.986 0.805 1.981
AADRR.48 3.641 2.635 6.161 0.86 0.994 0.788 1.582
ADDRR.182 3.752 2.247 6.152 0.92 0.995 0.838 1.662
DDRRR.175 3.742 2.187 6.142 0.91 0.996 0.837 1.852
DDRRR.179 3.742 2.187 6.142 0.91 0.996 0.837 1.852
ADRRR.252 3.647 2.241 6.138 0.88 0.973 0.793 1.844
DRRRR.113 3.643 2.004 6.134 0.89 0.972 0.786 1.963
DRRRR.173 3.643 2.004 6.134 0.89 0.972 0.786 1.963
DDRRR.13 3.607 2.078 6.127 0.89 0.991 0.731 1.828
DDRRR.23 3.607 2.078 6.127 0.89 0.991 0.731 1.828
ADRRR.262 3.726 2.310 6.126 0.90 0.990 0.838 1.884
AADRR.1 3.605 2.457 6.124 0.85 0.994 0.758 1.460
ADRRR.59 3.604 2.251 6.123 0.85 0.989 0.761 1.642
ADRRR.138 3.633 2.379 6.123 0.88 0.987 0.767 1.673
ADRRR.139 3.633 2.379 6.123 0.88 0.987 0.767 1.673
ADRRR.251 3.672 2.123 6.118 0.88 0.982 0.810 1.846
DRRRR.242 3.716 2.038 6.116 0.89 0.989 0.837 1.985
DRRRR.243 3.716 2.038 6.116 0.89 0.989 0.837 1.985
ADDRR.209 3.715 2.376 6.115 0.89 0.989 0.836 1.724
ADDRR.219 3.713 2.151 6.113 0.88 0.991 0.840 1.771
AADRR.186 3.712 2.601 6.112 0.90 0.995 0.822 1.591
ADDRR.77 3.712 2.480 6.112 0.89 0.995 0.829 1.605
ARRRR.13 3.591 2.197 6.111 0.81 0.985 0.801 1.800
DDRRR.211 3.711 2.107 6.111 0.88 0.990 0.837 1.955
AADRR.62 3.710 2.696 6.110 0.90 0.995 0.817 1.473
AADRR.175 3.663 2.583 6.110 0.88 0.99 0.797 1.544
ADRRR.160 3.710 2.535 6.110 0.88 0.989 0.841 1.745
AADDR.140 3.706 2.568 6.106 0.88 0.997 0.827 1.420
DDRRR.201 3.706 2.059 6.106 0.88 0.990 0.839 1.958
AADDR.134 3.703 2.505 6.103 0.89 0.995 0.814 1.391
ADDRR.183 3.635 1.972 6.102 0.87 0.991 0.774 1.661
AADDR.124 3.652 2.559 6.099 0.87 0.992 0.795 1.387
DRRRR.22 3.699 2.123 6.099 0.87 0.990 0.840 1.957
DRRRR.25 3.699 2.123 6.099 0.87 0.990 0.840 1.957
ADDRR.189 3.652 2.275 6.098 0.87 0.982 0.800 1.700
ADDRR.75 3.696 2.379 6.097 0.88 0.996 0.817 1.605
AADRR.2 3.650 2.664 6.096 0.88 0.992 0.779 1.466
ADDRR.81 3.696 2.150 6.095 0.87 0.998 0.823 1.621
ADDRR.84 3.696 2.150 6.095 0.87 0.998 0.823 1.621
ADRRR.10 3.695 2.243 6.095 0.89 0.996 0.811 1.666
DDRRR.14 3.691 2.139 6.090 0.90 0.991 0.795 1.829
DDRRR.24 3.691 2.139 6.090 0.90 0.991 0.795 1.829
AADDR.128 3.643 2.438 6.089 0.88 0.989 0.774 1.357
DRRRR.115 3.686 1.960 6.086 0.88 0.983 0.826 1.968
DRRRR.175 3.686 1.960 6.086 0.88 0.983 0.826 1.968
AADRR.196 3.682 2.522 6.082 0.86 0.990 0.834 1.606
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basis of the active and inactive sets, with a reward
assigned based on the pIC50 of each compound of the
data set. When a post-hoc scoreof >6.00 was taken to be
the cut-off value, 68 hypotheses survived and were then
used in the generation of QSAR models (Table 3). All
molecules in the dataset were then aligned, matching to at
least three pharmacophore features. Two different
approaches to splitting the dataset into training and test
sets were used: in the first, the compounds were randomly
divided into a 76-member training set and 19-member test
set, biasing both sets in order to give structural diversity to
them both, and employing the standard 4:1 training/test
ratio for a QSAR study. The other approach was based on
a Kohonen map artificial neural network or SOM (Fig. 3).
Descriptor calculations and autoscaling of the descriptor
matrix were the starting point when performing the
Kohonen clustering approach. The selected test set
members were characterized by the minimum distance
from the centroid of each cell in the top map. The standard
ratio (76/19 sets) was used in this approach too.
Both approaches to test-set selection selected the same
3D pharmacophore model, so this model was the only one
evaluated any further. This best model was DRRRR.115, in
which all active molecules in the active set matched the
hypothesis.
The Phase statistical analysis for each test-set selection
method is shown in Table 4. A statistical analysis that
included the R2 versus RMSE/SD plot was employed to
choose the best PLS model for each set selection method.
The best model was chosen on the basis of the PLS factor
model’s minimum RMSE/SD value, where the R2 value
was still higher than 0.9. The principle of the 5:1 training
set/PLS factor ratio was respected. The validity of each
model was tested based on the calculated correlation
coefficient for the test set. The squared correlation (random
Fig. 3 Kohonen top map
Table 3 (continued)
Hypothesis Survival Surv-inact Post-hoc Site Vector Volume Selectivity
AADRR.207 3.682 2.334 6.082 0.85 0.992 0.838 1.671
AARRR.41 3.680 2.384 6.080 0.85 0.990 0.842 1.705
AADRR.176 3.673 2.586 6.073 0.87 0.989 0.811 1.545
AADDR.154 3.669 2.292 6.069 0.85 0.991 0.830 1.440
ADDRR.8 3.666 2.414 6.066 0.86 0.990 0.814 1.591
AADDR.125 3.665 2.570 6.065 0.86 0.991 0.818 1.388
ARRRR.14 3.664 2.140 6.064 0.84 0.989 0.836 1.810
ARRRR.15 3.664 2.140 6.064 0.84 0.989 0.836 1.810
AADDR.129 3.657 2.444 6.057 0.88 0.989 0.791 1.358
AADDR.32 3.609 2.537 6.056 0.84 0.994 0.779 1.412
ADRRR.20 3.656 2.134 6.056 0.88 0.983 0.797 1.712
ADRRR.100 3.653 2.290 6.053 0.87 0.988 0.791 1.646
AARRR.8 3.605 2.404 6.051 0.81 0.983 0.810 1.698
AADDR.30 3.595 2.347 6.041 0.84 0.990 0.767 1.383
AADRR.187 3.641 2.476 6.041 0.85 0.987 0.803 1.610
AADDR.136 3.640 2.373 6.040 0.85 0.988 0.803 1.438
ARRRR.51 3.562 2.123 6.029 0.79 0.981 0.793 1.815
ARRRR.56 3.562 2.123 6.029 0.79 0.981 0.793 1.815
AARRR.42 3.575 2.221 6.022 0.80 0.975 0.805 1.714
AARRR.43 3.616 2.265 6.016 0.81 0.979 0.832 1.714
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selection Rpred
2=0.72), the Pearson R (=0.88), and the root
mean square error for test set predictions (RMSE=0.42) all
confirm the good predictive capabilities of the final QSAR
model for the test set. In the case of the Kohonen map
ANN, the model with five PLS factors was chosen as the
optimum one. The Rpred
2(=0.75), Pearson R(=0.87), and
RMSE(=0.44) values confirm the validity of this model
(Table 5; Fig. 4).
Analysis of the atom-based 3D-QSAR model
The best model, DRRRR.115, consists of four aromatic
rings and one hydrogen-bond donor. The spatial arrange-
ment of the pharmacophore sites shows that three aromatic
rings, two of which are very close to each other, occupy
the hydrophobic pocket created by the residues Val603,
Leu595, Leu799, Phe811, and Tyr672. The hydrogen-
bond donor site is located between the three aromatic
rings and the fourth one, which is 8–10 Å away from
the others (Fig. 5). The docking modes of the most active
inhibitors resemble the docking pose of imatinib. In fact,
for both the thienopyrimidines and aminobenzoisoxazoles,
fused aromatic rings lie in the hydrophobic pocket created
by the residues mentioned above. It should be emphasized
that in each case the interactions of the target with the
inhibitor are stabilized by at least two H-bonds. While the
residues involved are Asp810, Cys673, and Thr670 in the
case of imatinib, Glu640 and Glu671 are involved in the
inhibitors from the dataset. Only in the case of compound
71 does the number of H-bonds with Cys673 rise up to
four. For derivative 95, the residues involved are the same
as those for imatinib. The substantial difference between
imatinib and the inhibitors from the dataset is that the
former acts as an H-acceptor for two sites and as an H-
donor for one site, while the inhibitors from the dataset
have only donor sites. It should be underlined that,
although just one H-bond donor region and four aromatic
features are present in the best model (DRRRR.115),
analysis of the docking modes of the most active
inhibitors indicates the formation of more extensive
interaction patterns. However, in the pharmacophore
hypothesis, the only features common to all active
inhibitors in the data set are already taken into account.
Table 5 Results of 3D-QSAR analysis with the random selection method (a) and the Kohonen map method (b)
No. of factors SD R2 F RMSE Rpred
2 Pearson R RMSE/SD Δ Opt.model
(a)
1 0.6638 0.4078 51 0.5589 0.5155 0.7336 0.911 - -
2 0.5351 0.6203 59.6 0.4644 0.6654 0.833 0.997 0.086 -
3 0.4438 0.7424 69.2 0.5139 0.5903 0.8199 0.860 −0.137 -
4 0.34 0.8509 101 0.4521 0.683 0.8621 1.307 0.447 -
5 0.2321 0.9315 190 0.4605 0.6711 0.8565 1.923 0.616 -
6 0.1869 0.9562 251 0.4241 0.7209 0.8852 2.577 0.654 √
7 0.1445 0.9742 367 0.4165 0.7309 0.885 3.300 0.723 -
(b)
1 0.6187 0.4587 63.6 0.5635 0.5988 0.7999 0.842 - -
2 0.5262 0.6137 58.8 0.5244 0.6525 0.8141 0.868 0.026 -
3 0.4256 0.7507 73.3 0.366 0.8307 0.9349 1.158 0.29 -
4 0.3149 0.8654 116 0.4115 0.7861 0.8886 1.329 0.171 -
5 0.2328 0.9275 182 0.4477 0.7468 0.865 1.984 0.655 √
6 0.1745 0.9598 279 0.4497 0.7445 0.863 2.269 0.285 -
7 0.1373 0.9755 392 0.4531 0.7407 0.8608 2.882 0.613 -
Δ Difference from preceding
Table 4 Summary of the 3D-QSAR results
Statistical parameters Random selection
of test set
Kohonen map for
test set selection
R2 0.96 0.93
Number of molecules in
training set
76 76
Number of molecules
in test set
19 19
Optimum number of
components
6 5
SD 0.1869 0.2328
F value 251.3 181.6
Pearson R 0.88 0.87
RMSE 0.4241 0.4477
Rpred
2 0.72 0.75
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This means also that, for example, several compounds
present more than four aromatic rings, but only four are
common to all inhibitors. Figure 6 shows the volume
occlusion maps for the atom-based 3D-QSAR model
(donor, aromatic ring, electron-withdrawing features).
These maps represent the regions of favorable and
Fig. 5 Pharmacophore mapping of the most active compounds (left); superposition of active compounds on the pharmacophore
Fig. 4 Actual versus predicted values for training and test sets: a random, b Kohonen
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unfavorable interactions (shown in blue and red, respec-
tively). The volume occlusion map for the H-bond donor
describes the favorable 3D arrangement of hydrogen-
bonding interactions with acceptor groups of the protein.
The occlusion map surrounding the active molecules
shows blue cubes opposite the oxazole or pyrimidine ring,
which describe a favorable H-bond with an acceptor group
of the protein.
The volume occlusion map for the electron-withdrawing
groups indicates that the most suitable position for this kind
of group is in the external aromatic ring, while the presence
of these groups in the inner aromatic ring appears to be
unfavorable. This analysis indicates that improvements in
binding affinity can be achieved by adding electron-
withdrawing groups to the external aromatic ring. The
hydrophobic volume occlusion map shows mixed colora-
tion, indicating that an increase in the activity can be
expected if the marked hydrophobicity of inhibitors is
balanced by the presence of hydrophilic features or a
reduction in the hydrophobicity.
The model was further validated by assessing its
ability to pick out c-kit inhibitors in a known database
aside from the model dataset, using the goodness-of-hit
(GH score) approach [23]. For this external validation, a
database of 234 compounds was created which included
34 known c-kit inhibitors, the structures of which are
provided in the “Electronic supplementary material.” The
structures of the known inhibitors were taken from the
binding database. The other compounds employed in the
test set used for external validation were selected from
among the structures included in the ZINC database, with
care taken to ensure that none of the molecules was
structurally correlated with those in the original training
and test sets. A summary of the results is provided in
Table 6. When the 3D-QSAR model DRRRR.115 was
used to query this database, 28 molecules were retrieved
as hits (Ht); among these, 23 molecules were known
active inhibitors (Ha). The calculated GH score and
enrichment factor for the model were 0.74 and 4.83,
respectively. The numbers of false positives and false
negatives were 11 and 5, respectively. Thus, 82.14% of
the hits retried by the model from the database were
active inhibitors.
Conclusions
In summary, the goal of this study was to establish a strong
relationship between structural features and inhibitory
activity. Using a selected set of c-kit inhibitors, a 3D-
QSAR pharmacophore model was obtained, consisting of
one donor site and four aromatic rings. Volume occlusion
maps demonstrated that inhibitory activity can be increased
by modulating the donor abilities of the nitrogen or oxygen
atoms in the fused aromatic rings that are involved in the H-
bond interactions with the binding site of the receptor. This
model was validated by predicting the active inhibitors in a
test set prediction, and then by using it to pick active
inhibitors from a known database. The model generated can
be used to query databases and to provide guidelines when
designing more potent inhibitors.
Table 6 GH-score values
Property
Total number of compounds in database (D) 234
Total number of active inhibitors in database (A) 34
Total number of hits (Ht) 28
Number of hits that were active inhibitors (Ha) 23
% Yield of active inhibitors 82.14
% Ratio of active inhibitors to hits 67.64
Enrichment factor (E) 4.83
Number of false negatives 11
Number of false positives 5
GH score 0.75
Fig. 6 Occlusion maps. Left: hydrophobic; middle: donor; right: electron-withdrawing features
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